Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Tolerability and Effects of a New Omega-3 Fatty Acid-based Supplement on Clinical and Biological Markers of Healthy Ageing

Authors not listed

Helse Stavanger HF · 2023

Abstract

The goal of this randomised, double-blind placebo controlled trial is to explore tolerability and the effects of a new omega-3 fatty acid-based supplement on biological and clinical aspects relevant for healthy ageing. Participants will be asked to take a supplement or a placebo for 6 months, and to attend the clinic a total of 3 times and to perform or submit the following: * Physical examination * Muscle function tests * Cognitive testing * Questionnaire completion * Biological samples, including blood, saliva and faeces. Researchers will compare the results from the group taking the supplement to the results of the group taking a placebo to see if the supplement has an effect on biological and clinical aspects associated with healthy ageing.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-09 MST

Cite this

APA
Anonymous. (2023). Tolerability and Effects of a New Omega-3 Fatty Acid-based Supplement on Clinical and Biological Markers of Healthy Ageing. <em>Helse Stavanger HF</em>. https://clinicaltrials.gov/study/NCT06150261
Vancouver
Anonymous. Tolerability and Effects of a New Omega-3 Fatty Acid-based Supplement on Clinical and Biological Markers of Healthy Ageing. Helse Stavanger HF. 2023.
BibTeX
@misc{anon2023Tolera, title = {Tolerability and Effects of a New Omega-3 Fatty Acid-based Supplement on Clinical and Biological Markers of Healthy Ageing}, author = {Anonymous}, journal = {Helse Stavanger HF}, year = {2023}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings